Antibody screening approach could speed development of immune-based cancer treatments
· Medical Xpressby Jacqueline Mitchell, Harvard Medical School
edited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add to Preferred Sources
A team led by Harvard Medical School researchers at Beth Israel Deaconess Medical Center and Dana-Farber Cancer Institute has developed a faster way to identify and engineer cancer-fighting therapies.
In a study published in Nature Communications, the team used the new approach to create an investigational treatment that showed strong activity against aggressive B-cell lymphomas in laboratory experiments.
The approach, which the researchers are calling "tactical surfaceome profiling," is a novel strategy for identifying the most promising targets for immune-based therapies from among the molecules found on the surface of the malignant cells (collectively called the surfaceome).
The goal is to help macrophages—immune cells that identify, engulf, and dispose of diseased cells—recognize lymphoma cells more effectively, said co-first author Carlota Pagès-Geli, HMS research fellow in medicine at Beth Israel Deaconess in the lab of senior author Kipp Weiskopf.
Convincing immune cells to attack
B-cell lymphomas, which are among the most common blood cancers, arise from B cells, a type of white blood cell that helps protect the body from infection. Although immunotherapy treatments such as rituximab have transformed care for many patients, some lymphomas become resistant to therapy or return after treatment, creating the need to develop new therapeutic options.
Cancer cells often evade the immune system by displaying molecules on their surface that can fool macrophages, blunting the body's immune response to the disease.
Tactical surfaceome profiling begins by identifying the surface proteins that induce the desired immune response. This flips the script on decades of cancer research, since traditional drug discovery typically builds a drug tailored to a target first and then tests whether it demonstrates therapeutic potential only much later in the process.
Preclinical developments
To find the surface proteins most likely to help macrophages recognize and destroy cancer cells, the researchers used collections of antibodies targeting hundreds of proteins found on cell surfaces, including 173 mouse proteins and 241 human proteins.
The team then evaluated the 414 antibodies using a high-throughput screening platform, measuring how effectively each one flagged lymphoma cells for immune attack. The surface proteins corresponding to those top-performing antibodies emerged as the molecules most likely to serve as effective drug targets.
The researchers then engineered experimental antibodies to target a protein commonly found on lymphoma cells while also blocking a known molecular signal that tumors use to confuse and evade macrophages.
In laboratory studies, the most effective of these experimental antibodies triggered the killing of lymphoma cells by macrophages, including cells resistant to rituximab, and outperformed both rituximab and another drug used to treat blood cancers, called daratumumab, in several preclinical tests.
In mouse models of aggressive B-cell lymphoma, it slowed tumor growth, extended survival and, when combined with rituximab, eliminated tumors in some animals.
The investigators hope to advance these new therapies to clinical trials to assess their safety and efficacy in patients in the near future. Additionally, they are now applying tactical surfaceome profiling to other types of cancer, including gastric cancer, lung cancer and ovarian cancer.
Publication details
Carlota Pagès-Geli et al., High-throughput engineering of bispecific antibodies to enhance macrophage-mediated cytotoxicity of B-cell lymphoma, Nature Communications (2026). DOI: 10.1038/s41467-026-76180-5
Journal information: Nature Communications
Key medical concepts
Clinical categories
OncologyAllergy and immunology Provided by Harvard Medical School Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Antibody screening approach could speed development of immune-based cancer treatments (2026, October 15) retrieved 16 October 2026 from https://medicalxpress.com/news/2026-10-antibody-screening-approach-immune-based.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.